Raumedic plans to intensify its market focus with new leadership duo
Medical technology manufacturer Raumedic has re-assigned responsibilities amongst its top management team.
Executive board member Stefan Seuferling has been named chairman of the executive board of Raumedic AG by the company’s board of directors in a decision that took effect on March 15th.
Martin Bayer, the former chairman of the executive board of the Raumedic Group, will focus on his function as CEO and president of the U.S. associated company Raumedic in order to develop business in North America.
Jürgen Werner, the chairman of the board of directors, pointed out how the decision was designed to improve the position of the company in the respective markets. “Medical technology and the pharmaceutical industry face different requirements in each economic region,” Werner said. “In addition, customers are approaching Raumedic with highly individual product requests. With the new management structure, we want to enable both companies to retain their flexibility and to be highly responsive to their respective markets.”
The board of directors are the highest oversight authority for both companies. Werner discussed how with the new structure they work closely with the management team to ensure that the principle of “One Raumedic” is systematically applied.
Stefan Seuferling joined Raumedic AG in September 2018 as the executive board member responsible for strategy, from which position he leads sales activities in Europe and Asia. Seuferling also oversees the departments of marketing communication, quality management, regulatory affairs, as well as projects and services. Together with his executive board colleagues, Seuferling will lead the business activities of Raumedic AG as chairman of the executive board.
Under Bayer’s leadership, both sales and staffing nearly doubled from 2008 to 2018. Bayer intends to generate the same success in the USA that he previously produced for the global organisation.
“The new leadership team is the next logical step in our efforts to make Raumedic increasingly agile and market-centric,” Werner said. “We have the utmost confidence in Stefan Seuferling and Martin Bayer. We are certain that they can help the entire company continue generating sustainable and profitable growth. With this goal in mind, they will remain in close dialogue in the future.”